drugset / Trial / NCT05625035

Lianhua Qingwen for the Rehabilitation of Patient With Coronavirus Infection

NCT05625035 ↗

Phase 4 Unknown 4000 enrolled Qilu Hospital of Shandong University
RandomizedParallel-groupOpen-labelTreatment

Summary

The patients with coronavirus infection usually have fever, respiratory symptoms, headache, toothache, muscle soreness, physical decline, and so on, while others are asymptomatic patients. It is urgent to find drugs to improve the long-term rehabilitation of symptomatic patients with coronavirus infection and decrease the duration of viral shedding in both symptomatic and asymptomatic patients. This study aims to investigate the efficacy and safety of Lianhua Qingwen capsules in patients with coronavirus infection. The duration of viral shedding and symptoms before discharge, as well as the negative conversion ratio and disappearance ratio of main symptoms after 7-day treatment, will be evaluated. 6-month follow-up will be performed to evaluate the effect of Lianhua Qingwen on all infection events and the long-term rehabilitation of the symptoms induced by coronavirus infection.

Timeline

Start
2022-11-01
Primary completion
2023-06-30
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lianhua Qingwen capsules Unknown 4 unknown —

Indications